Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Gary M. Oderda"'
Autor:
A. Niyazov, Gary M. Oderda, Joseph Biskupiak, Ruben Gw Quek, Douglas S. Burgoyne, Linda S. Deal, Diana I. Brixner, Bhakti Arondekar
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:188-195
BACKGROUND: In oncology, especially with accelerated regulatory approvals and niche populations, US payers appreciate all evidence that can help support formulary decision making, including evidenc...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e053cd44d0a2f8edc1ba9f598d35c96
https://doi.org/10.18553/jmcp.2021.21223
https://doi.org/10.18553/jmcp.2021.21223
Publikováno v:
Pain Management. 12:45-57
Aim: HTX-011 (ZYNRELEF™) is an extended-release, dual-acting local anesthetic containing bupivacaine and meloxicam. In bunionectomy and herniorrhaphy studies, HTX-011 resulted in less postoperative pain and less opioid consumption versus bupivacain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddab82a1fdb28bd3bd468b9dfc9d6d28
https://doi.org/10.2217/pmt-2021-0043
https://doi.org/10.2217/pmt-2021-0043
Autor:
Joseph Biskupiak, Douglas S. Burgoyne, Diana I. Brixner, Gary M. Oderda, A. Niyazov, Bhakti Arondekar
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1560-1567
BACKGROUND: To support oncology formulary decisions, especially with accelerated regulatory approvals and niche populations, payers desire data beyond what regulators review. Economic models showin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bdee814c92211383dfc53e132a831c3
https://doi.org/10.18553/jmcp.2021.27.11.1560
https://doi.org/10.18553/jmcp.2021.27.11.1560
Autor:
Christina England, Nicole M. Zimmerman, Carolyn R. Lew, Chad M. Brummett, Amanda M. Kong, Jackie Evans-Shields, Gary M. Oderda, Caroline Henriques, Jayne Pawasauskas
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:973-983
The treatment of postsurgical pain with prescription opioids has been associated with persistent opioid use and increased health care utilization and costs.To compare the health care burden between opioid-naive adult patients who were prescribed opio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53bd450111abc9ed03bf684126fa3693
https://doi.org/10.18553/jmcp.2019.19055
https://doi.org/10.18553/jmcp.2019.19055
Autor:
David A. Edwards, Padma Gulur, Michael G. Mythen, Robert W. Hurley, Adam B. King, Debra B. Gordon, Andrew D. Shaw, Jennifer M. Hah, Tong J. Gan, Traci L. Hedrick, Michael L. Kent, Stefan D. Holubar, Jennifer Jayaram, Erin Sun, Julie K. M. Thacker, Michael C. Grant, Timothy M. Geiger, Charles Argoff, Gary M. Oderda, Ruchir Gupta, Matthew D. McEvoy, Timothy E. Miller, Christopher L. Wu, Michael P.W. Grocott
Publikováno v:
Anesthesia & Analgesia. 129:567-577
Surgical care episodes place opioid-naïve patients at risk for transitioning to new persistent postoperative opioid use. With one of the central principles being the application of multimodal pain interventions to reduce the reliance on opioid-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bed93c7771b6ff0e50a05fe1159f96
https://doi.org/10.1213/ane.0000000000004194
https://doi.org/10.1213/ane.0000000000004194
Autor:
David A. Edwards, Tong J. Gan, Padma Gulur, Ruchir Gupta, Matthew D. McEvoy, Michael G. Mythen, Christopher L. Wu, Timothy E. Miller, Timothy M. Geiger, Jennifer M. Hah, Traci L. Hedrick, Monty G. Mythen, Jennifer Jayaram, Erin Sun, Julie K. M. Thacker, Michael C. Grant, Michael L. Kent, Robert W. Hurley, Stefan D. Holubar, Eric C. Sun, Debra B. Gordon, Andrew D. Shaw, Adam B. King, Michael P.W. Grocott, Charles Argoff, Gary M. Oderda
Publikováno v:
Anesth Analg
Persistent postoperative opioid use is thought to contribute to the ongoing opioid epidemic in the United States. However, efforts to study and address the issue have been stymied by the lack of a standard definition, which has also hampered efforts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1862101246337ea41b99effaab178c52
https://doi.org/10.1213/ane.0000000000003941
https://doi.org/10.1213/ane.0000000000003941
Autor:
Derek H. Tang, Christopher Zacker, Anand A. Dalal, Joseph Biskupiak, Diana I. Brixner, Gary M. Oderda
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:859-866
Discarding unused drugs after dose changes or discontinuation can significantly affect pharmacy budgets. This is especially concerning for expensive oncology agents. However, few economic studies account for drug wastage, providing an inaccurate esti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a31516752fe8952d95b64faa149d3594
https://doi.org/10.18553/jmcp.2019.25.8.859
https://doi.org/10.18553/jmcp.2019.25.8.859
Autor:
Peter J. Neumann, Tatia Chay Woodward, Nik Seifter, Joseph Biskupiak, Gary M. Oderda, Diana I. Brixner, Martin Marciniak
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:164-173
Preapproval information exchange (PIE) is the communication of clinical and health care economic information (HCEI) on therapies in development between U.S. population health decision makers (PHDMs) and drug manufacturers before regulatory approval.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e9a716c4c59fff2c284c2a3bf01305
https://doi.org/10.18553/jmcp.2019.25.2.164
https://doi.org/10.18553/jmcp.2019.25.2.164
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:18-27
Reliance on prescription opioids to manage pain has been associated with increases in diversion, overdose, and addiction. Prevalence of misuse and abuse has been shown to be higher among government-insured populations than commercially insured popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daff6bb215d7b48d98ba9387804603aa
https://doi.org/10.18553/jmcp.2019.25.1.018
https://doi.org/10.18553/jmcp.2019.25.1.018
Autor:
Mukesh Kumar Singh, Beilei Cai, Nisha C Hazra, Weiguang Xue, Zheng-Yi Zhou, Dinesh Mishra, Gary M. Oderda, Joseph Biskupiak, Diana I. Brixner
To estimate the budget impact of adding capmatinib, the first FDA approved MET inhibitor, to a US commercial or Medicare health plan for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have a mutation that leads to MET exon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76f6a947374ed43408c3c682b81d3ec
